ImmunityBio, Inc. or Mesoblast Limited: Who Manages SG&A Costs Better?

ImmunityBio vs. Mesoblast: A Decade of SG&A Management

In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, ImmunityBio, Inc. and Mesoblast Limited have showcased contrasting strategies. ImmunityBio's SG&A expenses fluctuated significantly, peaking in 2015 with a staggering 2,262% increase from the previous year. In contrast, Mesoblast maintained a more stable trajectory, with expenses peaking in 2015 but only increasing by 21% from 2014. By 2023, ImmunityBio's expenses were approximately 2.4 times higher than Mesoblast's, highlighting a more aggressive spending approach. However, Mesoblast's consistent management might suggest a more sustainable model. The data reveals a missing entry for ImmunityBio in 2024, indicating potential reporting gaps. As these companies navigate the biotech sector's challenges, their SG&A strategies will be pivotal in determining long-term success.